Welcome to our dedicated page for AGENUS SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AGENUS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AGENUS's regulatory disclosures and financial reporting.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 4,852 shares of common stock on July 10, 2026 as a grant in lieu of cash salary. The shares represent the net amount of his salary for that pay period, are issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and are fully vested on the date of issuance. The share amount is based on the $3.35 closing price of Agenus common stock on July 10, 2026. Following this award, Armen holds 371,108 shares directly, plus additional indirect holdings through IRA accounts and trust and partnership entities.
Agenus Inc. entered into a securities purchase agreement for a private placement expected to close on July 15, 2026. The company will issue and sell 23,035,227 shares of common stock (or equivalent pre-funded warrants), Series A warrants for 21,144,277 shares at an exercise price of $4.02, and Series B warrants for 33,797,214 shares at $5.03. The combined effective purchase price per share plus accompanying warrants is $3.69, providing approximately $85 million in upfront gross proceeds and up to an additional $255 million upon full warrant exercise, for total potential gross proceeds of up to $340 million.
The financing supports a strategic prioritization of the botensilimab and balstilimab (BOT+BAL) regimen for neoadjuvant treatment of microsatellite-stable colon cancer, including the planned 850-patient Phase 3 ROBBIN trial with event-free survival as the primary endpoint. Agenus plans to discontinue financial support for the BATTMAN Phase 3 metastatic study. Based on current plans, existing cash plus net proceeds are expected to fund operations into the third quarter of 2027 without warrant exercise and through year-end 2031 if all Series A and B warrants are fully exercised. The company also agreed to add two Commodore Capital–designated directors as part of expanding its board to nine members and entered into a registration rights agreement to register resale of the shares and warrant shares.
AGENUS INC director Thomas L. Harrison received a grant of 8,547 shares of common stock on July 1, 2026. These shares were acquired under the company’s Board Compensation Election Policy, where directors can take their fees in stock. At a reference price of $3.583 per share, his direct holdings increased to 47,545 shares.
AGENUS INC director Timothy Wright reported a routine compensation grant of Deferred Stock Units. On July 1, 2026, he acquired 2,267.765 Deferred Stock Units, each tied to the company’s common stock on a 1-for-1 basis under the directors’ deferred compensation plan.
The units were valued at $3.583 per Deferred Stock Unit, based on the average closing price of the company’s stock during the prior calendar quarter. Following this award, Wright holds a total of 26,180.771 Deferred Stock Units, which are typically settled in common shares after he ceases serving as a director.
Agenus Inc. entered into an agreement with existing noteholders that extends the maturity of $5.09 million of senior subordinated promissory notes from June 20, 2026 to February 18, 2027, keeping all other note terms the same.
The company also extended to June 25, 2031 the expiration dates of three existing warrant series covering an aggregate 165,000 shares of common stock, all at an exercise price of $3.25 per share. In addition, Agenus issued new 2026 D Warrants to certain noteholders to purchase 56,525 shares at the same exercise price, also expiring on June 25, 2031. The shares issuable under the new D Warrants are expected to be registered for resale within 90 days after June 29, 2026.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received company stock as salary instead of cash for the pay period ending June 26, 2026. He was granted 5,364 shares of common stock, representing the net amount of his salary, at a reference price of $3.03 per share, which was the closing price on June 26, 2026. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, bringing his directly held common stock to 366,256 shares. The filing also notes indirect holdings through IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT with 23,950 shares and the Pixie Partners general partnership with 5,000 shares, where he has only a partial pecuniary interest in the partnership’s shares.
Agenus Inc. reported results of its Annual Meeting of Stockholders held on June 16, 2026, where 27,098,077 shares, or 65.24% of shares eligible to vote, were represented, establishing a quorum. Stockholders elected Class II directors Garo Armen and Jennifer Buell for three-year terms and approved amendments to the 2019 Employee Stock Purchase Plan, increasing shares authorized from 150,000 to 200,000, and to the 2019 Equity Incentive Plan, adding 5,000,000 shares available for issuance. They also approved a one-time stock option exchange program, endorsed 2025 executive compensation in a non-binding advisory vote, and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. executive and director Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. The shares were valued using the closing price of $3.30 on that date and are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. After this grant, Dr. Armen holds 360,892 shares directly, along with additional indirect holdings through IRA accounts and entities referenced in the footnotes.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,644 shares of Common Stock as compensation paid in stock instead of cash. The shares were valued at $3.50 per share, equal to the closing price on May 29, 2026, and were fully vested on the grant date.
After this grant, Dr. Armen directly holds 355,967 shares of Common Stock. He also has indirect holdings through IRA accounts and entities, including a GRAT holding 23,950 shares and a general partnership holding 5,000 shares in which he has only a partial pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received a grant of 4,540 shares of common stock for the pay period ending May 15, 2026, as salary paid in stock instead of cash. The shares were issued fully vested under the company’s 2019 equity incentive plan at a reference price of $3.58, the closing price on May 15, 2026.
Following this grant, Dr. Armen directly holds 351,323 common shares, with additional indirect holdings in IRA accounts and entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.